Company Overview
ALX Oncology Holdings Inc. operates as a clinical-stage immuno-oncology company dedicated to developing advanced therapies specifically for cancer patients within the United States market. The organization functions within the broader Healthcare sector, focusing its operational efforts on the specialized Biotechnology industry, which implies a reliance on intensive research and development to bring novel treatments to clinical trials. The company maintains a relatively small organizational structure with a workforce of 43 employees, supporting its clinical-stage status and specific product focus. Its current market capitalization stands at $268.48M, while annual revenue figures are not disclosed in the available data, indicating that the entity is still in a phase where capital is primarily directed toward development rather than commercialization. This valuation suggests the company is priced based on future potential and clinical milestones rather than current operational profitability, positioning it as a capital-intensive entity typical of early-stage biotechnology firms that require significant funding to advance their lead product candidates.
Financial Health
The company reports a net income of $-101,695,000 for the trailing twelve months, while EBITDA stands at $-100,140,000, reflecting substantial operational losses inherent to the clinical-stage development phase. The absence of reported revenue data combined with these significant negative net income figures reveals a cost structure heavily weighted toward research, development, and clinical trial expenses rather than sales and marketing costs. Free cash flow is reported at $-50,609,000, indicating that the company is currently burning cash at a rate that necessitates external financing or the utilization of existing cash reserves to sustain operations. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which indicates that the company has not yet generated sufficient commercial revenue to calculate meaningful profitability percentages, a common characteristic of firms in the pre-revenue stage. On the balance sheet, the company holds $44.79M in cash against $14.77M in debt, resulting in a debt-to-equity ratio of 56.85, which suggests a leveraged position relative to equity but one supported by a significant cash buffer. The current ratio is 2.07, indicating that the company possesses more than double the liquid assets required to cover its short-term liabilities, suggesting adequate short-term liquidity despite the burn rate. Return on Equity is -145.7% and Return on Assets is -61.0%, metrics that reveal the dilutive impact of ongoing losses on shareholder value and the efficiency of asset utilization in the current developmental phase.
Valuation Assessment
The trailing twelve-month P/E ratio is not available due to the lack of earnings, while the forward P/E is listed at -3.32, a negative metric that implies earnings are expected to remain negative or that the valuation model is adjusting for the absence of current profits. The price-to-book ratio is 4.27, indicating that the market values the company at a significant premium over its book value, likely reflecting high expectations regarding the potential success of its lead product candidate, Evorpacept. Alternative valuation metrics such as the EV/EBITDA of -2.38 and the unavailable price-to-sales ratio further highlight that traditional multiple-based comparisons are limited in this context, as the company is not yet generating positive cash flows or sales. The stock has traded within a 52-week range with a high of $2.66 and a low of $0.40, meaning the current market price sits somewhere within this wide volatility band, though the exact current price is not provided in the source data to calculate a precise percentage deviation. The beta value is 0.50, which suggests that the stock exhibits lower price volatility relative to the broader market, moving roughly half as much as the market index during periods of general fluctuation.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, indicating that the company is not yet in a growth phase driven by expanding commercial sales but rather by clinical progression. Since the company is not a dividend payer, the dividend yield and payout ratio are both N/A or 0.0%, meaning the company does not distribute income to shareholders and instead reinvests all available capital and retained earnings into its research and development pipeline. This reinvestment strategy is standard for clinical-stage biotechnology companies that prioritize advancing their immuno-oncology portfolio over returning capital to investors. Consequently, the overall growth and income profile for ALX Oncology Holdings Inc. is defined entirely by clinical milestones and the potential for future commercialization of its therapies rather than current financial returns or dividend income.